Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Will · SciRah

Researcher profile · Semantic Scholar

M. Will

Share profile

M. Will — researcher profile on SciRah

h-index: 5
Works: 17
Citations: 153

Most-cited papers

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
G. Salles, S. Schuster, S. de Vos, N. Wagner-Johnston +14 more
2017Haematologica65 citations Open access
Semantic Scholar
2-Acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of Cyclin E expression
C. Trautwein, M. Will, Stefan Kubicka, T. Rakemann +2 more
1999Oncogene41 citations
Semantic Scholar
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
J. García-Corbacho, A. Spira, V. Boni, J. Feliu +7 more
201711 citations Open access
Semantic Scholar
CD70 is a potential target biomarker in peripheral T‐cell lymphomas
M. Marques-Piubelli, J. Sagert, M. Pham, M. Will +13 more
2022Histopathology8 citations
Semantic Scholar
Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study.
P. Zinzani, P. Ghia, G. Salles, S. Schuster +10 more
20157 citations
Semantic Scholar
DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia
Kelly Shi, C. Tan, Lu Bai, Jennifer L. Richardson +10 more
2022Blood4 citations Open access
Semantic Scholar
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.
K. Autio, H. Arkenau, B. O'Neil, J. Bendell +14 more
20183 citations
Semantic Scholar
Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.
V. Boni, J. García-Corbacho, P. Ott, D. Cho +9 more
2018Annals of Oncology3 citations Open access
Semantic Scholar
Abstract LB-185: Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the Probody drug conjugate CX-2009 in patients with advanced solid tumors
F. Meric-Bernstam, V. Boni, A. Spira, R. Sanborn +9 more
2019Immunology2 citations
Semantic Scholar
Abstract 212: CD166-DM4 probody drug conjugate (CX-2009) treatment of 198 patient-derived xenograft models (PDX) in a mouse clinical trial format
Bob Y. Liu, Joel Shen, M. Will, Sreeni Yalamanchili +8 more
2019Experimental and Molecular Therapeutics2 citations
Semantic Scholar
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.
R. Plummer, R. Sanborn, E. D. de Vries, P. Lorusso +12 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.
R. Sanborn, C. W. Menke, K. Autio, H. Arkenau +13 more
20182 citations
Semantic Scholar
Abstract 6595: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells
Sushant Karnik, M. Pham, P. Keerthipati, Zinkal Padalia +6 more
2020Immunology1 citations
Semantic Scholar
Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072
S. Adams, E. Hamilton, P. Ott, D. Cho +7 more
2019Poster Session Abstracts1 citations
Semantic Scholar
Cyclin e is the primary target of activated ras in regeneratinghepatocyte and is regulated by post-transcriptional mechanisms
T. Lüdde, Jörg Plümpe, M. Will, M. Lüdde +3 more
20001 citations
Semantic Scholar
Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.
M. Stroh, L. Serwer, Hong Lu, Vanessa Huels +8 more
20180 citations
Semantic Scholar
The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas
V. Boni, J. García-Corbacho, J. Feliu, J. Wydmański +6 more
20170 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Boni×6
Invite
V. Boni — researcher profile on SciRah
H. Arkenau×5
Invite
H. Arkenau — researcher profile on SciRah
R. Humphrey×5
Invite
R. Humphrey — researcher profile on SciRah
J. García-Corbacho×4
Invite
J. García-Corbacho — researcher profile on SciRah

×4

Invite

A. Spira — researcher profile on SciRah

Invite

K. Autio — researcher profile on SciRah

Invite

N. Uboha — researcher profile on SciRah

F. Thistlethwaite×4

Invite

F. Thistlethwaite — researcher profile on SciRah

A. El-Khoueiry×3

Invite

A. El-Khoueiry — researcher profile on SciRah

Beiyao Zheng×3

Invite

Beiyao Zheng — researcher profile on SciRah

Invite

M. Stroh — researcher profile on SciRah

E. D. de Vries×3

Invite

E. D. de Vries — researcher profile on SciRah